AMGEN ANNOUNCES WEBCAST OF 2025 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS

Rhea-AI Summary

Amgen (NASDAQ:AMGN) will report fourth quarter and full year 2025 financial results on Tuesday, February 3, 2026, after U.S. market close. A conference call with management will follow at 4:30 p.m. ET, and live audio webcast will be available on Amgen's Investor Relations site.

The webcast will be archived and available for replay for at least 90 days on the company's website.

Key Figures

Earnings release date: February 3, 2026 Conference call time: 4:30 p.m. ET Webcast replay period: 90 days

3 metrics

Earnings release date February 3, 2026 Scheduled Q4 and full-year 2025 results announcement

Conference call time 4:30 p.m. ET Investor conference call following results release

Webcast replay period 90 days Minimum time webcast will remain available

Market Reality Check

Price: $342.20 Vol: Volume 3,132,450 is 1.21x...

normal vol

$342.20 Last Close

Volume Volume 3,132,450 is 1.21x the 20-day average of 2,589,713, showing modest pre-earnings interest. normal

Technical Shares at $351.32 trade above the 200-day MA of $300.16 and sit 0.55% below the 52-week high of $353.25.

Peers on Argus

AMGN gained 0.47% with moderately higher volume while large-cap peers were mostl...

AMGN gained 0.47% with moderately higher volume while large-cap peers were mostly positive (e.g., GILD +2.49%, PFE +2.16%, BMY +1.83%) but without momentum-scanner confirmation, indicating a stock-specific, event-timing headline rather than a broad sector move.

Previous Earnings Reports

5 past events · Latest: Nov 04 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Nov 04	Q3 2025 results	Positive	+0.1%	Strong Q3 2025 revenue and EPS growth with reiterated full-year guidance.
Oct 29	Q3 2025 webcast	Neutral	+0.1%	Scheduled Q3 2025 results date and investor webcast details.
Aug 05	Q2 2025 results	Positive	-5.1%	Strong Q2 revenue and EPS with multiple products showing double-digit growth.
Jul 31	Q2 2025 webcast	Neutral	+0.6%	Announcement of Q2 2025 release timing and conference call logistics.
May 01	Q1 2025 results	Positive	-0.9%	Q1 2025 revenue and EPS growth with improved margins and cash flow.

Pattern Detected

Earnings webcasts and results have typically produced relatively small moves, with some positive quarters followed by negative price reactions.

Recent Company History

Recent earnings-related news for Amgen shows consistent operational strength. In Q1–Q3 2025, revenues grew, with Q3 2025 revenue at $9.6 billion and GAAP EPS of $5.93. Management repeatedly reiterated 2025 revenue and EPS guidance. Webcast announcements on May 1, July 31, and October 29, 2025 preceded results calls and saw modest price moves between about 0.08% and 0.60%. Actual earnings releases sometimes led to downside moves despite strong numbers, underscoring that expectations were already high heading into results.

Historical Comparison

earnings

+1.4 %

Average Historical Move

Historical Analysis

In the past year, AMGN’s 5 earnings-tagged events averaged a 1.37% move. Webcast announcements like this one historically saw relatively small, muted price reactions.

Typical Pattern

Earnings updates have progressed through Q1, Q2, and Q3 2025 with recurring revenue and EPS growth and reiterated 2025 guidance, and this Q4/FY 2025 webcast continues that established quarterly disclosure cadence.

Market Pulse Summary

This announcement schedules Amgen’s Q4 and full-year 2025 results for February 3, 2026, with a confe...

Analysis

This announcement schedules Amgen’s Q4 and full-year 2025 results for February 3, 2026, with a conference call at 4:30 p.m. ET and a webcast replay available for at least 90 days. Historically, similar webcasts produced modest price moves, while actual earnings releases sometimes diverged from strong reported metrics. Investors watching this event typically focus on revenue growth, EPS trends, guidance updates, and how new information compares with prior quarters.

AI-generated analysis. Not financial advice.

THOUSAND OAKS, Calif., Jan. 28, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2025 financial results on Tuesday, February 3, 2026, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 4:30 p.m. ET. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team.

Live audio of the conference call will be simultaneously broadcast over the internet and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

About Amgen
Amgen discovers, develops, manufactures and delivers innovative medicines to fight some of the world's toughest diseases. Harnessing the best of biology and technology, Amgen reaches millions of patients with its medicines. 

More than 45 years ago, Amgen helped establish the biotechnology industry at its U.S. headquarters in Thousand Oaks, California, and it remains at the cutting edge of innovation, using technology and human genetic data to push beyond what is known today. Amgen is advancing a broad and deep pipeline and portfolio of medicines to treat cancer, heart disease, inflammatory conditions, rare diseases and obesity and obesity-related conditions.  

Amgen has been consistently recognized for innovation and workplace culture, including honors from Fast Company and Forbes. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average^®, and it is also part of the Nasdaq-100 Index^®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization.  

For more information, visit Amgen.com and follow Amgen on X, LinkedIn, Instagram, YouTube, Facebook, TikTok and Threads. 

CONTACT: Amgen, Thousand Oaks
Elissa Snook, 609-251-1407 (media)
Casey Capparelli, 805-447-1746 (investors)  

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/amgen-announces-webcast-of-2025-fourth-quarter-and-full-year-financial-results-302673138.html

SOURCE Amgen

FAQ

When will Amgen (AMGN) release its Q4 and full year 2025 results?

Amgen will release Q4 and full year 2025 results on Tuesday, February 3, 2026, after market close. According to Amgen, a conference call with management follows at 4:30 p.m. ET and a live webcast will be available on the Investor Relations site for public access.

How can investors access the Amgen (AMGN) webcast for the February 3, 2026 results?

Investors can access the live webcast on Amgen's Investor Relations website at www.amgen.com under Investors. According to Amgen, the audio broadcast will be simultaneous and viewers should check the Investor Relations Events Calendar for links and presentation times.

Who will participate on Amgen's (AMGN) February 3, 2026 earnings call?

Amgen's chairman and chief executive officer Robert A. Bradway and other senior management will participate on the call. According to Amgen, the management team will present results and take questions during the 4:30 p.m. ET conference call following the earnings release.

What time is the Amgen (AMGN) Q4 2025 conference call on February 3, 2026?

The conference call is scheduled for 4:30 p.m. ET on February 3, 2026, immediately after the results release. According to Amgen, live audio will be broadcast over the internet and the webcast link is listed on the company's Investor Relations Events Calendar.

How long will Amgen (AMGN) archive the Q4 and full year 2025 webcast replay?

Amgen will archive the webcast replay for at least 90 days after the event. According to Amgen, archived audio and presentation materials will remain available via the Investor Relations site for media, investors, and the general public to replay.